availability of compounded semaglutide May 2025 - CompoundedGLP-1 ban May 2025 The Shifting Landscape of Compounded Semaglutide Availability

Compounded semaglutideban The availability of compounded semaglutide has been a topic of significant discussion and recent regulatory shifts, primarily influenced by the semaglutide shortage and subsequent FDA policy changes.2025年3月12日—✔️ You can continue receivingcompounded semaglutideuntil April 20 (tentative date). ✔️ After that date, you will need to switch to either:. While compounded semaglutide has served as an alternative during periods of scarcity, understanding its current status and future outlook is crucial for patients and healthcare providersAre Compounded GLP-1s Going Away? Not Entirely.

For a considerable period, semaglutide and tirzepatide experienced a shortage that commenced in 2022 due to surging demand. This scarcity created a gap that compounding pharmacies aimed to fill by producing compounded semaglutide. This practice leverages the FDA's regulations that permit the creation of compounded drug products when the commercially available versions are not readily accessible.2026年2月4日—FDA is aware of fraudulentcompounded semaglutideand tirzepatide marketed in the U.S. that contain false information on the product label. In ... A compounded drug product is essentially understood as a copy of a drug that is commercially available2025年11月14日—Semaglutideis commercially available... A compounded drug product is considered essentially a copy of a commercially available drug product..

However, the situation began to change with the FDA's removal of semaglutide from the drug shortage list on February 21, 2025Why the FDA is cracking down on compound GLP-1 drugs .... This announcement marked a significant turning point, indicating that the primary condition allowing for the general compounding of semaglutide was no longer presentWhy the FDA is cracking down on compound GLP-1 drugs .... Subsequently, the FDA clarified its policies, leading to a phased reduction in the availability of compounded semaglutideGlobal Rise of Compounded Weight-Loss Medicines - PMC. Many sources indicate that, as of May 2025, compounded semaglutide will no longer be legally available in many contexts, with specific deadlines for cessation of production and dispensing varying slightly by state and pharmacy2025年3月3日—Now that there is no longer a semaglutide shortage,compounded semaglutide won't be legally available after May 2025.. For instance, some compounding pharmacies were mandated to cease making most compounded semaglutide by April 22nd of that year.

The FDA's stance is that they do not typically allow the compounding of commercially available drugs unless the drug is not readily available and is listed on the FDA drug shortage list.Companies find ways around end of GLP-1 shortage With the semaglutide shortage is over, the rationale for widespread compounding of semaglutide diminishes significantly. This regulatory shift has substantial implications for telehealth companies like Hims & Hers that built business models around the availability of compounded semaglutide. While some platforms have confirmed their intention to continue offering compounded semaglutide to eligible patients for a limited time, pending upcoming FDA restrictions, the general consensus points towards a future where its availability will be significantly curtailed or eliminated for most patientsAre Compounded GLP-1s Going Away? Not Entirely.

It's important to note that compounded semaglutide has never been FDA-approved for any indication, unlike its brand-name counterparts, Ozempic® and Wegovy®. The FDA's concerns have also extended to the quality and labeling of some compounded versions2025年2月28日—The FDA's recent decision to removesemaglutidefrom the drug shortage list marks a significant shift forcompoundingpharmacies.. In February 2026, the FDA highlighted concerns regarding fraudulent compounded semaglutide and tirzepatide marketed in the U.SDid the FDA ban compounded semaglutide?. that contained false product information. Furthermore, pharmaceutical manufacturers like Novo Nordisk and Eli Lilly have issued cease-and-desist letters, asserting that you cannot legally compound semaglutide or tirzepatide except in rare, documented cases of true medical necessity.2025年4月21日—FDA's announcement that approved versions ofsemaglutideare no longer in shortage is unlikely to stop the use of unapprovedcompoundedversions ...

While semaglutide is no longer eligible for general compounding, the FDA's drug shortage list does include other GLP-1 drugs, such as dulaglutide and liraglutide, which may still be candidates for compounding under specific circumstances. For patients who have been relying on compounded semaglutide, understanding these changes is paramount. As of April 2025, some providers have stated they no longer offer compounded semaglutide or tirzepatide.2026年2月19日—You cannot legally compound semaglutideor tirzepatide except in rare, documented cases of true medical necessity. Consult a healthcare attorney ...

The period from 2022 through early 2025 represented a unique chapter where compounded semaglutide played a crucial role in addressing the semaglutide and tirzepatide shortage. However, with the resolution of these shortages, the regulatory environment has shifted, impacting the availability of compounded drugs.FDA Announces End to Semaglutide Shortage, Impacting ... The exact timeline and specific regulations can vary, so consulting with a healthcare professional and staying informed about the latest FDA guidance is recommended.Why the FDA is cracking down on compound GLP-1 drugs ... Some sources suggest that while the FDA has resolved the semaglutide shortage, the availability of compounded semaglutide may persist in some states, with one mention of available in 46 states. Despite these nuances, the overarching trend indicates a move away from widespread compounding of semaglutide as the supply of FDA-approved versions stabilizes.